Why One Value Fund Has a $101 Million Bet on Indivior Stock Amid a 212% Surge

Event-driven manager Newtyn Management bought nearly 1.6 million Indivior shares in Q3, lifting its position to $101.3M (12.4% of U.S. equity assets) and making Indivior its top holding. Indivior reported Q3 revenue of $314M and adjusted EBITDA of $120M (both up ~14% YoY for EBITDA; SUBLOCADE grew 15% and contributed $219M), has raised full-year revenue guidance to roughly $1.2B, and expects a 2025 adjusted-EBITDA midpoint implying ~15% growth while pursuing cost cuts and market exits to deliver ~$150M in annual savings from 2026. Newtyn’s sizable accumulation signals conviction in the company’s turnaround and margin inflection, likely drawing additional investor attention even as the company remains levered.

Analysis

Market structure: Newtyn’s large Q3 accumulation materially tightens free float demand for INDV and signal-checks other event/value funds — direct winners are Indivior (INDV) equity holders, SUBLOCADE commercial partners, and clinics benefiting from injectables; losers are smaller buprenorphine generics and markets where Indivior is exiting (UK/Ireland). With SUBLOCADE accounting for ~70% of Q3 revenue ($219M of $314M), pricing power for the depot franchise is high but concentrated, and Newtyn’s stake (12.4% of US equity assets) creates a technical bid that can compress borrow and reduce options skew near-term.

Risk assessment: Key tail risks are regulatory/Medicaid reimbursement changes, a clinical or manufacturing setback to SUBLOCADE, or renewed legacy legal exposures that could re-lever the balance sheet; any of these could wipe out >50% of market cap fast given concentrated revenues. Immediate (days) effects are modest technical support; short-term (weeks–months) hinges on Q4 guidance and execution of cost cuts; long-term (2026+) depends on realizing $150M annualized OpEx savings and deleveraging to reduce default/credit risk.

Trade implications: Direct play: constructive on INDV with a tactical size (1–3% portfolio) and a staggered buy-on-dip plan (add if price falls >10% to $31; stop-loss $26). Use a 12–18 month horizon to capture margin/cash-flow improvement to a $50 target (40%+ upside) while using option structures (defined-risk call spreads) to leverage. Sector trades: overweight specialty pharma/behavioral health providers, underweight high-burn biotechs; consider pair trades to isolate product execution risk.

Contrarian angles: Consensus underweights the concentration risk — market pricing may be underestimating reimbursement cut risk and R&D shrinkage after the geographic exits; Newtyn’s conviction could be liquidity-driven rather than fundamental. Historical parallels (single-product turnarounds) show upside if cost-savings are executed but permanent impairment if access erodes; watch patient starts and Medicaid coverage over next 2–6 quarters as the real demand signal.

Key Decisions for Investors

• Establish a 1–3% long position in INDV (ticker INDV): tranche 40% now, 60% on pullback below $31 (≈10% down); set stop-loss at $26 and target $50 within 12–18 months (risk/reward ~+40% vs -25%).
• Buy a defined-risk long call spread to leverage upside: Jan 2026 INDV 40/60 call spread (net debit) sized to equal 0.5–1.0% portfolio risk — captures upside from margin recovery while limiting premium decay.
• Pair trade to isolate execution: go long INDV (1.0% notional) and short Alkermes (ALKS) 0.75% notional; rebalance weekly and close if relative performance diverges >15% or if INDV misses next quarterly guide.
• Avoid Indivior corporate credit until leverage improves; only consider bond exposure if senior spreads tighten <250bps over Treasuries and management provides a clear 2026 deleveraging plan with quarterly milestones.